Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Get Free Report) EVP Eric Swayze sold 1,194 shares of Ionis Pharmaceuticals stock in a transaction dated Tuesday, November 12th. The stock was sold at an average price of $37.92, for a total transaction of $45,276.48. Following the transaction, the executive vice president now directly owns 33,713 shares in the company, valued at $1,278,396.96. This trade represents a 3.42 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.
Eric Swayze also recently made the following trade(s):
- On Wednesday, October 16th, Eric Swayze sold 53 shares of Ionis Pharmaceuticals stock. The stock was sold at an average price of $38.31, for a total value of $2,030.43.
Ionis Pharmaceuticals Stock Performance
NASDAQ:IONS traded down $1.72 during trading hours on Friday, reaching $35.51. The company had a trading volume of 248,925 shares, compared to its average volume of 1,309,919. The stock has a 50-day moving average of $39.87 and a two-hundred day moving average of $42.80. Ionis Pharmaceuticals, Inc. has a one year low of $35.37 and a one year high of $54.44. The company has a debt-to-equity ratio of 1.86, a quick ratio of 8.82 and a current ratio of 8.91.
Analyst Upgrades and Downgrades
Trump said you could learn something from this man
From Wide Moat Research | Ad
Early Warning: A Deep Crack Is Forming In The US Economy
Stocks are booming thanks to Trump’s landslide victory. Yet one former Trump advisor says the picture is less rosy than it seems. “I’ve found a deep crack forming in the foundations of the US economy,” he says. “And before too long, it could tear our country apart.” It’s critical you learn more today, BEFORE it impacts your money and your retirement.
Here’s everything you need to know.
A number of analysts recently weighed in on the stock. Guggenheim cut their target price on shares of Ionis Pharmaceuticals from $70.00 to $65.00 and set a "buy" rating on the stock in a research note on Wednesday, October 9th. Leerink Partners raised shares of Ionis Pharmaceuticals from a "market perform" rating to an "outperform" rating and boosted their price objective for the company from $53.00 to $62.00 in a research note on Wednesday, July 24th. Leerink Partnrs upgraded Ionis Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Wednesday, July 24th. The Goldman Sachs Group boosted their target price on Ionis Pharmaceuticals from $33.00 to $37.00 and gave the stock a "sell" rating in a research report on Friday, August 2nd. Finally, Royal Bank of Canada reiterated an "outperform" rating and issued a $70.00 target price on shares of Ionis Pharmaceuticals in a research note on Thursday, September 26th. Two analysts have rated the stock with a sell rating, five have assigned a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Ionis Pharmaceuticals has an average rating of "Moderate Buy" and a consensus target price of $60.65.
Read Our Latest Stock Report on Ionis Pharmaceuticals
Institutional Inflows and Outflows
Several institutional investors have recently bought and sold shares of the stock. GAMMA Investing LLC boosted its position in shares of Ionis Pharmaceuticals by 83.9% during the third quarter. GAMMA Investing LLC now owns 664 shares of the company's stock worth $27,000 after purchasing an additional 303 shares in the last quarter. nVerses Capital LLC acquired a new stake in Ionis Pharmaceuticals during the 2nd quarter worth approximately $29,000. Itau Unibanco Holding S.A. bought a new stake in shares of Ionis Pharmaceuticals during the second quarter worth $37,000. Mather Group LLC. raised its holdings in shares of Ionis Pharmaceuticals by 35.8% during the second quarter. Mather Group LLC. now owns 911 shares of the company's stock worth $39,000 after acquiring an additional 240 shares during the period. Finally, Capital Performance Advisors LLP bought a new stake in Ionis Pharmaceuticals in the 3rd quarter valued at $40,000. Institutional investors own 93.86% of the company's stock.
Ionis Pharmaceuticals Company Profile
(
Get Free Report)
Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
